Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVP^TM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood cancer for which there are a variety of treatment options, requiring patients to work closely with their doctors to determine the right plan to meet their needs.

Multiple myeloma has hit home for the baseball community in recent years, which is why Amgen is partnering with former Major League Baseball (MLB) All-Stars Dave Winfield and Steve Garvey, who have both been touched by multiple myeloma, to encourage patients to play a proactive role in their care by developing an individualized treatment plan. Former MLB All-Star Don Baylor passed away from multiple myeloma in 2017 following a 14-year battle with the disease. Baylor's son, Don Baylor Jr., is honoring his father's legacy by also participating in the campaign and raising awareness of multiple myeloma.

"I knew Don Baylor for nearly 40 years from our playing days. He was my teammate, a groomsman in my wedding and one of my best friends," said Winfield. "On the field, as a player, coach and manager, he always had a plan in approaching the day's game. Off the field, he took the same approach in managing his multiple myeloma. I'm honored to work with Amgen on Myeloma MVP to help raise awareness of this incurable blood cancer and encourage patients to create a plan for managing their disease."

The multiple myeloma treatment landscape has evolved significantly over the past decade, changing the expectations of physicians and patients. In order to create the right plan, patients need to have a voice in their treatment. Doctors should be aware of their patients' priorities and treatment goals, which may include attending an upcoming wedding or continuing a favorite outdoor activity while receiving treatment, or generally living as long as possible.

The Myeloma MVP guide, available at MyelomaExplained.com, asks a series of questions to help patients think through their priorities before their next oncology appointment, so they can work with their doctor to create the best plan for them.

As part of the campaign, Amgen is working closely with the multiple myeloma patient research and advocacy community, including the Multiple Myeloma Research Foundation (MMRF), the International Myeloma Foundation (IMF) and Myeloma Crowd, to raise awareness with patients and caregivers. Amgen will also work with MLB to recognize local multiple myeloma communities at select games during the 2018 season.

"My dad went through cycles of remission and relapse and experienced weakness in his bones, but he didn't let multiple myeloma stop him from doing what he loved every day. He coached in the big leagues for 12 years after his diagnosis," said Baylor Jr. "What I learned from my dad's experience is that while multiple myeloma is complex, feeling empowered to work with your doctor to develop the right strategy can help manage the disease. I look forward to working with Amgen, Dave and Steve to help bring awareness to this new tool for patients."

"Don Baylor was a dear personal friend and a tremendous advocate for multiple myeloma patients. Don worked tirelessly to build awareness, promote research and educate patients about this disease. We are so proud to see members of the baseball community continue his wonderful legacy," said Paul Giusti, president and chief executive officer of the MMRF. "At the MMRF, we understand the importance of patients and caregivers being educated, empowered and taking an active role in their treatment. We are pleased to be involved with such an important project."

The Myeloma MVP guide is available now on Amgen's new patient education website, MyelomaExplained.com, along with additional information and resources for patients living with this disease, including:

• Multiple myeloma FAQ: Frequently asked questions about the disease, including signs and symptoms, risk factors and more.
• Management options: What to expect following a diagnosis, as well as treatment and supportive care information.
• Understanding your treatment: Tips and questions to help facilitate a productive conversation with your physician.
• Team video: A shareable video featuring Winfield, Garvey and Baylor Jr., intended to broaden awareness of the campaign and need for patients to create a plan.

"Myeloma MVP is an important initiative for Amgen, as we continue to focus on finding new and innovative ways to help patients living with multiple myeloma," said Robert Cuddihy, M.D., vice president of U.S. Medical at Amgen. "Based on our own research, we've seen a disconnect between patient goals and treatment decisions. This program provides a tool that helps both patients and physicians create a plan together to better manage their disease."

About Dave Winfield
Twelve-time MLB All-Star and Hall-of-Famer Dave Winfield knows the impact multiple myeloma can have on a patient all too well. In 2017, his close friend and former teammate Don Baylor passed away following a 14-year battle with the disease. Together, with Don's son, Don Jr., Dave is committed to helping raise awareness of this incurable blood cancer.

About Steve Garvey
Steve Garvey is a 10-time MLB All-Star and former World Series champion. He saw firsthand the impact of multiple myeloma when his father-in-law was diagnosed and later passed away from the disease. A former prostate cancer patient himself, Steve is urging patients to play an active role in their treatment by creating a plan for managing multiple myeloma.

About Don Baylor Jr.
Don Baylor Jr. is the son of former MLB player and coach Don Baylor, who passed away following a 14-year battle with multiple myeloma. Following his diagnosis, Don Sr. worked hard to raise awareness and fund to help fight this incurable disease. Don Jr. has partnered with Amgen to build on his father's work.

About Amgen's Commitment to Oncology
Amgen Oncology is committed to helping patients take on some of the toughest cancers, such as those that have been resistant to drugs, those that progress rapidly through the body and those where limited treatment options exist. Amgen's supportive care treatments help patients combat certain side effects of strong chemotherapy, and our targeted medicines and immunotherapies focus on more than a dozen different malignancies, ranging from blood cancers to solid tumors. With decades of experience providing therapies for cancer patients, Amgen continues to grow its portfolio of innovative and biosimilar oncology medicines.

For more information, follow us on www.twitter.com/amgenoncology.

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on  Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: 
Amgen, Thousand Oaks
Andrea Fassacesia, 805-905-2575 (Media)
Kristen Davis, 805-447-3008 (Media)

SOURCE Amgen

Related Links

https://www.amgen.com